Bradley Pharmaceuticals — Proxy Contest (October 2006)
30 slides from Bradley Pharmaceuticals's proxy contest presentation, Oct 11, 2006
Slide 1: Costa Brava Partnership III L.P. Presentation to Stockholders of Bradley Pharmaceuticals
Costa Brava Partnership III L.P. Presentation ite) Stockholders of Bradley Pharmaceuticals, Inc. October 2006
Slide 2: Not your typical small-cap investor
Costa Brava Partnership III L.P. Not your typical small-cap investor Costa Brava Partnership III L.P. Woes Brava’) is an investment fund with approximately $165 million of assets under management. Costa Brava often invests in companies that we believe are undervalued because of special situations, i
Slide 3: Costa Brava's investment strategy produces results
Costa Brava Partnership II] L.P. (cont.) Costa Brava’s investment strategy produces results, including the following: « Riscorp - Persuaded majority stockholder to pay full value for company, maximizing value for all stockholders. « Huntsman Polymer - Persuaded company to repurchase defaulted securi
Slide 4: Bradley Pharmaceuticals, Inc.
Bradley Pharmaceuticals, Inc. (NYSE:BDY) « Costa Brava made its initial investment in Bradley Pharmaceuticals, Inc. (“Bradley” or the “Company’), a specialty pharmaceutical company, in February 2005. « Costa Brava has maintained a long position in Bradley since its initial investment. « Today, Costa
Slide 5: The Two Faces of Bradley
The Two Faces of Bradley + Bradley is a solvent, growing company that generates substantial cash flow. From modest entrepreneurial beginnings, Bradley has grown to a size that now provides numerous strategic alternatives that can greatly enhance stockholder value over the next few years. This is why
Slide 6: The Troubled State of Affairs at Bradley
the Troubled State of Affairs at Bradley + Bradley has demonstrated a complete disregard for sound principles of corporate governance. The Company’s Board of Directors is plagued by a fundamental lack of independence and has failed to be accountable to the Company's public stockholders. + Poor corpo
Slide 7: The Troubled State of Affairs at Bradley (cont.)
The Troubled State of Affairs at Bradley (cont.) Bradley's history is marked by a failure to act until being forced to do so. On numerous occasions, the Company has disregarded stockholders’ rights until legal action was instituted to enforce those rights. Similarly, only after Costa Brava institute
Slide 8: Bradley's Stock Performance July 2004 to July 2006
Bradley's Stock Performance from July 19, 2004 to July 18, 2006, the two year period preceding Costa Brava’s announcement that it intended to nominate three candidates for election to the Boa Quote in USD ‘BradeyPharmacadicalsin(NYSEBDY)- Coron Stock BradeyPharracetticalsie (NYSEBDY)- Common Stock-
Slide 9: A Fundamental Lack of Independence on the Board of Directors
A Fundamental Lack of Independence on the Board of Directors « The Company's Class B common stock (the “Class B Shares’), the entirety oF which is owned by CEO Dan Glassman and his family, has the power to elect a majority of the Board of Directors. Despite the fact that the Class B Shares represent
Slide 10: A Fundamental Lack of Independence on the Board (cont.)
A Fundamental Lack of Independence on the Board of Directors (cont.) « A majority of the members of the Compensation Committee and the Nominating and Corporate Governance Committee are composed of directors elected by the Class B Shares. So even the Board committees that determine executive compensa
Slide 11: ... and Poor Corporate Governance at Bradley Does Not End There
... and Poor Corporate Governance at Bradley Does Not End There. « CEO and executive compensation is not in alignment with the Company's financial performance or public stockholder concerns (see Slides 18 through 20). « Asystem that rewards nepotism. Bradley Glassman, the son of CEO and Chairman of
Slide 12: Limited Rights Afforded by the Company's Organizational Documents
Limited Rights Afforded by the Company’s Organizational Documents Bradley’s dual class capital structure is only one way that the Company limits the rights afforded to its public stockholders: The Company’s organizational documents do not permit stockholders to call special meetings. The Board of Di
Slide 13: Poor Corporate Governance Has Not Come Without a Cost
Poor Corporate Governance Has Not Come Without a Cost to Bradley's Public Stockholders + In December 2004, the SEC announced that it was conducting an inquiry into Bradley's potential violation of federal securities laws, including the Company's revenue recognition practices. « Fora period of over o
Slide 14: Financial Control Issues
Financial Control Issues Bradley was forced to restate its third quarter 2004 financial results, resulting in the Form 10-Q being filed with the SEC 14 months late. Bradley's Form 10-K for fiscal 2004 was filed 11 months late. Bradley's Form 10-Q for the first quarter of 2005 was filed 10 months lat
Slide 15: Financial Transparency Issues
Financial Transparency Issues > Returns and return provisions increased significantly from 2004 through 2006, resulting in erratic net sales figures. » SG&A percentages have also been erratic due to extra legal, investigative, audit, and director fees. » Bradley stated that the delays in filing its
Slide 16: Return Reserve Provision
Return Reserve Provision [= Retum reserve provision Return reserves as a % of Gross Sales Thousands of dollars 638% | 5 and, an angst 1004 2004 3004 4004 1005 2005 3005 4005 1006 2006
Slide 17: Gross Sales are trending up consistently over the past two years
“Gross Sales’ are trending up consistently over the past two years... 5,000 0 2005 4005 1006 2008 ._ While net sales are more erratic... We want the lines to be parallel. We want transparency. 7
Slide 18: Troubled Times at Bradley... Unless You Were An Executive Officer
Troubled Times at Bradley... Unless You Were An Executive Officer of ihe Company As the Company’s financial performance deteriorated and its stock lost Beers ainacely 60% of its value: + CEO Dan Glassman, his son Bradley and other executive officers of the Company received guaranteed employment agre
Slide 19: Dan Glassman's Salary 2003-2005
Dan Glassman’s Salary 2003-2005 A 8 = G z 4 $750,000 $700,000 $650,000 $600,000 $550,000 $500,000 $450,000 $400,000 $19,000,000 $17,000,000 $15,000,000 $13,000,000 $11,000,000 $9,000,000 $7,000,000 2004 $5,000,000 2005 —— Daniel Glassman Salary Net income i
Slide 20: ... and Excessive Compensation Did Not End There
... and Excessive Compensation Did Not End There. As current financial statements remained unavailable to the Company’s public stockholders throughout 2005: The Company rewarded Dan Glassman with a “non- accountable expense allowance” of $25,000 per year. The Company rewarded its named executive off
Slide 21: What Costa Brava is not attempting to do
What Costa Brava is not attempting to do... + We are not trying to “take over” Bradley. « We are not recommending that Bradley be sold. + We are not recommending that Bradley use its substantial cash balance for share repurchases. « We are not recommending that Bradley incur significantly more debt,
Slide 22: What Costa Brava and its nominees will work to accomplish
What Costa Brava and its nominees will work to accomplish . . . « Obtaining an independent voice for the Company's public stockholders, one that is not controlled by or affiliated with the Glassmans. + Improving corporate governance, financial transparency and financial controls at Bradley. + Workin
Slide 23: Douglas Linton has the specific skill set to address return reserve provisions
Douglas Linton has the specific skill set to address the issue of excessive return reserve provisions Doug was one of the top five officers at Cardinal Health (formerly known as Cardinal Distribution) at the time that it became a public company. Cardinal Health is now ‘one of the top three drug whol
Slide 24: John Ross has the specific skill set to evaluate growth initiatives
John Ross has the specific skill set to evaluate Bradley's growth initiatives and oversee their successful implementation John was a co-founder, investor and board member of MetaWorks Inc. MetaWorks’ statistical analyses are employed to support pharmaceutical product claims with respect to both regu
Slide 25: Seth Hamot has the experience necessary to improve corporate governance
Seth Hamot has the experience necessary to remedy and improve corporate governance practices at Bradley « Seth has a proven track record of implementing improved corporate governance practices at the companies that he invests in. « Seth has experience protecting the rights of security holders as a p
Slide 26: A vote for the Costa Brava nominees is a vote for:
A vote for the Costa Brava nominees is a vote for: Director nominees that are truly independent in every sense of the word, Costa Brava’s nominees were not elected by the Glassman family and were not nominated by a Board committee controlled by Glassman-elected directors. Director nominees who will
Slide 27: Our Commitment to Improved Corporate Governance
Our Commitment to Improved Corporate Governance If elected to the Board of Directors of Bradley, our nominees will work to institute the following improvements to corporate governance: Split the roles of Chief Executive Officer and Chairman of the Board of Directors. There is an inherent lack of ove
Slide 28: What is Bradley offering the public stockholders?
What is Bradley offering the public stockholders? A vague commitment to increase stockholder value. Are conference calls and attendance at analyst meetings the answer to a fundamental lack of independence on the Board Of Directors? Director nominees that lack independence from the Glassmans, includi
Slide 29: Bradley's Future Is Bleak Without the Costa Brava Nominees
Bradley’s Future Is Bleak Without the Costa Brava Nominees History has demonstrated that Bradley cannot be expected to act on its own, and will only act when pressured or required to do so. Without an independent voice on the Board of Directors, Bradley will continue to operate with the same conflic
Slide 30: Searchable text section
Searchable text section Costa Brava Partnership III L.P. Presentation to Stockholders of Bradley Pharmaceuticals, Inc. October 2006 Costa Brava Partnership III L.P. Not your typical small-cap investor Costa Brava Partnership III L.P. ("Costa Brava") is an investment fund with approximately $165 mill
Bradley Pharmaceuticals — Proxy Contest (October 2006) on 6ix